Updated 20 December 2011
In the two previous posts I have outlined what I believe to be the active phase III and II/III cell therapy trials, as well as the cell therapy products to have 'recently' obtained formal regulatory market approval in some jurisdiction.
In the course of doing that work, I came across the following industry-sponsored phase III cell therapy trials which appear to be inactive and those which failed or were terminated.
INACTIVE INDUSTRY PHASE III or II/III
- Aastrom BRCs
- Aldagen ALD-101
- Arblast AMT-301
- Avax Mvax
- Vioheart Myocell
- HepaLife Tech HepaMate
- KeraCure KeraPac
- Northwest Bio DCVax-Prostate
- t2cure BMCs
- TVAX TV-Brain
- TVAX TV-Kidney-1
RECENTLY FAILED /TERMINATED INDUSTRY PHASE III
- ABH (now Shire) Dermgraft
- Cellerix Cx401
I don't imagine this is an exhaustive list but as I have encouraged in previous posts, I welcome feedback as to errors, corrections, or omissions. I'm using the 2009-11 time-frame here. I'll update the post accordingly.
